A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer After Prior Trastuzumab and Pertuzumab

Detalles Bibliográficos
Autores principales: Fischer, Stefanie, Götze, Thorsten O., Omlin, Aurelius, Baird, Richard D., Dawson, Keith M., Zitt, Christof, Arany, Zita, Tresch, Gaby, Fiedler, Ulrike, Jeger, Simone, Fung, Samson, Legenne, Philippe, Leupin, Nicolas, Schneeweiss, Andreas, Fremd, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666114/
https://www.ncbi.nlm.nih.gov/pubmed/36331248
http://dx.doi.org/10.1200/PO.22.00006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9666114/
https://www.ncbi.nlm.nih.gov/pubmed/36331248
http://dx.doi.org/10.1200/PO.22.00006

Ejemplares similares